<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Pyxis Oncology Inc — News on 6ix</title>
<link>https://6ix.com/company/pyxis-oncology-inc</link>
<description>Latest news and press releases for Pyxis Oncology Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 17 Apr 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/pyxis-oncology-inc" rel="self" type="application/rss+xml" />
<item>
<title>Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026</title>
<link>https://6ix.com/company/pyxis-oncology-inc/news/pyxis-oncology-to-present-new-preclinical-data-showing-synergistic-anti-tumor-activity-in-a-hnscc-model-with-mamicvo-in-combination-with-anti-pd-1-at-aacr-2026</link>
<guid isPermaLink="true">https://6ix.com/company/pyxis-oncology-inc/news/pyxis-oncology-to-present-new-preclinical-data-showing-synergistic-anti-tumor-activity-in-a-hnscc-model-with-mamicvo-in-combination-with-anti-pd-1-at-aacr-2026</guid>
<pubDate>Fri, 17 Apr 2026 20:05:00 GMT</pubDate>
<description>Mouse analog of MICVO (maMICVO) monotherapy produced dose-dependent inhibition of tumor growth in a syngeneic preclinical model of HNSCC maMICVO monotherapy modulated the tumor-immune environment in a syngeneic preclinical model of HNSCC toward a more favorable immune-permissive environment for immunotherapy maMICVO in combination with anti-mouse PD-1 worked synergistically to produce greater anti-tumor activity compared with either treatment alone in an immune-refractory syngeneic preclinical m</description>
</item>
<item>
<title>Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/pyxis-oncology-inc/news/pyxis-oncology-provides-business-update-and-reports-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/pyxis-oncology-inc/news/pyxis-oncology-provides-business-update-and-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Mon, 23 Mar 2026 04:00:00 GMT</pubDate>
<description>Completed target enrollment in Phase 1 monotherapy dose expansion study of micvotabart pelidotin (MICVO) in 2L+ Recurrent/Metastatic Head and Neck Squamous</description>
</item>
<item>
<title>Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity</title>
<link>https://6ix.com/company/pyxis-oncology-inc/news/pyxis-oncology-announces-interim-ceo-114500781</link>
<guid isPermaLink="true">https://6ix.com/company/pyxis-oncology-inc/news/pyxis-oncology-announces-interim-ceo-114500781</guid>
<pubDate>Tue, 03 Feb 2026 11:45:00 GMT</pubDate>
<description>BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a leadership transition to continue execution and advancement of the Company’s strategic and clinical goals. Thomas Civik, a member of Pyxis Oncology’s Board of Directors since the Company’s IPO and a highly experienced biotechnology executive with a proven track record in advancing cancer therapeutics, has</description>
</item>
<item>
<title>Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma</title>
<link>https://6ix.com/company/pyxis-oncology-inc/news/pyxis-oncology-announces-positive-preliminary-120000786</link>
<guid isPermaLink="true">https://6ix.com/company/pyxis-oncology-inc/news/pyxis-oncology-announces-positive-preliminary-120000786</guid>
<pubDate>Thu, 18 Dec 2025 12:00:00 GMT</pubDate>
<description>46% confirmed objective response rate (ORR) and 92% disease control rate (DCR) observed with MICVO as monotherapy in 2L+ R/M HNSCC at 5.4 mg/kg 71% confirmed ORR and 100% DCR observed with MICVO in combination with KEYTRUDA® (pembrolizumab) in 1L/2L+ R/M HNSCC at 3.6 mg/kg and 4.4 mg/kgUpdated data from ongoing Phase 1 monotherapy study in 2L+ R/M HNSCC expected mid-2026; updated data from ongoing Phase 1/2 study evaluating MICVO in combination with KEYTRUDA®, including in 1L/2L+ R/M HNSCC and o</description>
</item>
<item>
<title>Pyxis Oncology to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/pyxis-oncology-inc/news/pyxis-oncology-participate-upcoming-investor-210500136</link>
<guid isPermaLink="true">https://6ix.com/company/pyxis-oncology-inc/news/pyxis-oncology-participate-upcoming-investor-210500136</guid>
<pubDate>Mon, 03 Nov 2025 21:05:00 GMT</pubDate>
<description>BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that management will participate in the following upcoming investor conferences in November 2025: Guggenheim 2nd Annual Healthcare Innovation Conference, Boston, MA, Monday, November 10, 2:30 p.m. ET. – Fireside chat.Stifel 2025 Healthcare Conference, New York, NY, Tuesday, November 11, 4:00 p.m. ET. – Fire</description>
</item>
<item>
<title>Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/pyxis-oncology-inc/news/pyxis-oncology-provides-business-reports-120000899</link>
<guid isPermaLink="true">https://6ix.com/company/pyxis-oncology-inc/news/pyxis-oncology-provides-business-reports-120000899</guid>
<pubDate>Mon, 03 Nov 2025 12:00:00 GMT</pubDate>
<description>- Preliminary data from ongoing Phase 1 clinical studies of micvotabart pelidotin (MICVO) in patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) expected in the fourth quarter of 2025 - Clinical update to focus on preliminary data from Phase 1 monotherapy dose expansion study of MICVO in 2L/3L R/M HNSCC patients, including from both post platinum & PD-1 and post EGFR & PD-1 arms, and preliminary data from Phase 1/2 combination dose escalation study of MICVO a</description>
</item>
<item>
<title>Pyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical Meetings</title>
<link>https://6ix.com/company/pyxis-oncology-inc/news/pyxis-oncology-present-translational-data-200500713</link>
<guid isPermaLink="true">https://6ix.com/company/pyxis-oncology-inc/news/pyxis-oncology-present-translational-data-200500713</guid>
<pubDate>Mon, 13 Oct 2025 20:05:00 GMT</pubDate>
<description>Translational data validate mechanism of first-in-concept extracellular-cleaving ADC micvotabart pelidotin (MICVO) MICVO combats solid tumors through three-pronged mechanism of action: direct tumor cell killing, bystander effect, and immunogenic cell death Findings demonstrate MICVO’s effects on tumor microenvironment remodeling and immune activation Translational data to be presented in two posters at ESMO 2025 and six posters at AACR-NCI-EORTC BOSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Pyxis On</description>
</item>
<item>
<title>Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets</title>
<link>https://6ix.com/company/pyxis-oncology-inc/news/pyxis-oncology-appoints-alex-kane-113000103</link>
<guid isPermaLink="true">https://6ix.com/company/pyxis-oncology-inc/news/pyxis-oncology-appoints-alex-kane-113000103</guid>
<pubDate>Thu, 09 Oct 2025 11:30:00 GMT</pubDate>
<description>BOSTON, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing antibody-drug conjugate (ADC) therapeutics for difficult-to-treat cancers, today announced the appointment of Alex Kane, MBA, as Senior Vice President, Investor Relations & Capital Markets, effective immediately. Mr. Kane brings 20 years of experience and a proven track record in investor relations, strategic communications, and equity capital markets across the life sciences sector</description>
</item>
<item>
<title>Maxion Therapeutics Appoints Joel Edwards as Chief Business Officer</title>
<link>https://6ix.com/company/pyxis-oncology-inc/news/maxion-therapeutics-appoints-joel-edwards-as-chief-business-officer</link>
<guid isPermaLink="true">https://6ix.com/company/pyxis-oncology-inc/news/maxion-therapeutics-appoints-joel-edwards-as-chief-business-officer</guid>
<pubDate>Wed, 01 Oct 2025 12:18:00 GMT</pubDate>
<description>Cambridge, UK, 1 October 2025 – Maxion Therapeutics (“Maxion”), a biotechnology company developing antibody-based KnotBody® drugs for ion channel and G protein coupled receptor (GPCR)-driven diseases, today announces the appointment of Joel Edwards as Chief Business Officer (CBO), effective immediately. Joel brings over 25 years of global experience in corporate strategy, operations, business development and alliance management, having secured more than $3.5 billion in strategic partnering reven</description>
</item>
<item>
<title>Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/pyxis-oncology-inc/news/pyxis-oncology-reports-inducement-grants-202400606</link>
<guid isPermaLink="true">https://6ix.com/company/pyxis-oncology-inc/news/pyxis-oncology-reports-inducement-grants-202400606</guid>
<pubDate>Tue, 30 Sep 2025 20:24:00 GMT</pubDate>
<description>BOSTON, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation antibody-drug conjugate (‘ADC’) therapeutics for difficult-to-treat cancers, reported today that Pyxis Oncology’s Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 382,518 shares of Pyxis Oncology’s common stock to seven newly hired employees. The awards were granted under the Pyxis Oncology, Inc. 2022 Inducement Plan</description>
</item>
<item>
<title>Pyxis Oncology to Participate in September Investor and Industry Conferences</title>
<link>https://6ix.com/company/pyxis-oncology-inc/news/pyxis-oncology-participate-september-investor-113000278</link>
<guid isPermaLink="true">https://6ix.com/company/pyxis-oncology-inc/news/pyxis-oncology-participate-september-investor-113000278</guid>
<pubDate>Thu, 21 Aug 2025 11:30:00 GMT</pubDate>
<description>BOSTON, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing antibody-drug conjugate (ADC) therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President, Chief Executive Officer and Chief Medical Officer, will participate in the following upcoming conferences. Investor Conferences 2025 Cantor Global Healthcare Conference, New York, NY, Wednesday, September 3, 2:45 p.m. ET – Fireside chat and investor one-</description>
</item>
<item>
<title>Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/pyxis-oncology-inc/news/pyxis-oncology-reports-second-quarter-200500771</link>
<guid isPermaLink="true">https://6ix.com/company/pyxis-oncology-inc/news/pyxis-oncology-reports-second-quarter-200500771</guid>
<pubDate>Thu, 14 Aug 2025 20:05:00 GMT</pubDate>
<description>– Phase 1 monotherapy expansion study of micvotabart pelidotin (MICVO) for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients progressing well with preliminary data in second half of 2025 and first half of 2026 – Phase 1/2 combination study of MICVO and KEYTRUDA® (pembrolizumab) progressing well with preliminary data in second half of 2025 – Received a $2.8 million, net of tax, milestone payment from Simcere Pharmaceutical Group Limited for approval of suvemcitug</description>
</item>
<item>
<title>Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/pyxis-oncology-inc/news/pyxis-oncology-reports-first-quarter-110000812</link>
<guid isPermaLink="true">https://6ix.com/company/pyxis-oncology-inc/news/pyxis-oncology-reports-first-quarter-110000812</guid>
<pubDate>Thu, 15 May 2025 11:00:00 GMT</pubDate>
<description>- Announced robust preclinical data supporting the unique three-pronged mechanism of action of micvotabart pelidotin (MICVO, formerly PYX-201), driving anti-tumor activity via direct tumor killing, bystander effect and immunogenic cell death - On track to report preliminary data from Phase 1 monotherapy expansion cohorts of MICVO for 2L/3L R/M HNSCC patients who have received prior platinum-based chemotherapy and prior PD-(L)1 inhibitor therapy in second half of 2025, and 2L/3L R/M HNSCC patient</description>
</item>
<item>
<title>Pyxis Oncology to Participate in Two Upcoming Investor Conferences</title>
<link>https://6ix.com/company/pyxis-oncology-inc/news/pyxis-oncology-participate-two-upcoming-113000508</link>
<guid isPermaLink="true">https://6ix.com/company/pyxis-oncology-inc/news/pyxis-oncology-participate-two-upcoming-113000508</guid>
<pubDate>Wed, 14 May 2025 11:30:00 GMT</pubDate>
<description>BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation ADC therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President, Chief Executive Officer and Chief Medical Officer, will participate in fireside chats and be available for one-on-one meetings with investors at the following two upcoming investor conferences. 2025 RBC Capital Markets Global Healthcare Conference in New York, NY o</description>
</item>
<item>
<title>Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC</title>
<link>https://6ix.com/company/pyxis-oncology-inc/news/pyxis-oncology-presents-promising-preclinical-171700556</link>
<guid isPermaLink="true">https://6ix.com/company/pyxis-oncology-inc/news/pyxis-oncology-presents-promising-preclinical-171700556</guid>
<pubDate>Fri, 25 Apr 2025 17:17:00 GMT</pubDate>
<description>Gene signatures associated with increased efficacy of micvotabart pelidotin (MICVO) due to greater linker cleavage were identified based on differential gene expression analysis of PDX responders/non-responders Mouse analog of MICVO in a syngeneic model indicated strong activity of the cytotoxic Auristatin0101 payload and potential for MICVO monotherapy to drive immunogenic cell death, a key hypothesis for MICVO’s mechanism Combination of a mouse analog of MICVO and anti-PD-1 therapy in a syngen</description>
</item>
<item>
<title>Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum</title>
<link>https://6ix.com/company/pyxis-oncology-inc/news/pyxis-oncology-participate-stifel-2025-113000420</link>
<guid isPermaLink="true">https://6ix.com/company/pyxis-oncology-inc/news/pyxis-oncology-participate-stifel-2025-113000420</guid>
<pubDate>Wed, 02 Apr 2025 11:30:00 GMT</pubDate>
<description>BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President, Chief Executive Officer and Chief Medical Officer, will participate in a fireside chat at the Stifel 2025 Virtual Targeted Oncology Forum on Wednesday, April 9, 2025, at 11:30 a.m. ET. The Company will also be holding one-on-one investor meetings at the event. A live</description>
</item>
<item>
<title>Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025</title>
<link>https://6ix.com/company/pyxis-oncology-inc/news/pyxis-oncology-present-preclinical-data-203000831</link>
<guid isPermaLink="true">https://6ix.com/company/pyxis-oncology-inc/news/pyxis-oncology-present-preclinical-data-203000831</guid>
<pubDate>Tue, 25 Mar 2025 20:30:00 GMT</pubDate>
<description>Expression data from patient-derived xenograft (PDX) mouse models exposed to micvotabart pelidotin (MICVO) indicate gene signatures associated with efficacy, deepening understanding of MOA and potential patient response Combination of a mouse analog of MICVO and a mouse anti-PD-1 therapy in a syngeneic model resulted in significantly greater tumor regression than either treatment alone Company advances MICVO into monotherapy and combination clinical trials with Merck’s anti-PD-1 therapy, Keytrud</description>
</item>
<item>
<title>Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/pyxis-oncology-inc/news/pyxis-oncology-reports-fourth-quarter-113000058</link>
<guid isPermaLink="true">https://6ix.com/company/pyxis-oncology-inc/news/pyxis-oncology-reports-fourth-quarter-113000058</guid>
<pubDate>Tue, 18 Mar 2025 11:30:00 GMT</pubDate>
<description>- Recently reported positive preliminary data from Phase 1 dose escalation trial of micvotabart pelidotin (“MICVO,” formerly PYX-201), including a confirmed 50% objective response rate by RECIST 1.1 in recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) - Received Fast Track Designation from the U.S. Food and Drug Administration for MICVO for the treatment of adult patients with R/M HNSCC whose disease has progressed following treatment with platinum-based chemotherapy and</description>
</item>
<item>
<title>Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference</title>
<link>https://6ix.com/company/pyxis-oncology-inc/news/pyxis-oncology-participate-leerink-partners-123000891</link>
<guid isPermaLink="true">https://6ix.com/company/pyxis-oncology-inc/news/pyxis-oncology-participate-leerink-partners-123000891</guid>
<pubDate>Mon, 03 Mar 2025 12:30:00 GMT</pubDate>
<description>BOSTON, March 03, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a fireside chat on Monday, March 10, 2025 at 2:20 PM EST at the Leerink Partners Global Healthcare Conference in Miami, Florida. A live webcast and replay of the fireside chat will be available on the Events & Presentat</description>
</item>
<item>
<title>Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer</title>
<link>https://6ix.com/company/pyxis-oncology-inc/news/pyxis-oncology-granted-fda-fast-123000542</link>
<guid isPermaLink="true">https://6ix.com/company/pyxis-oncology-inc/news/pyxis-oncology-granted-fda-fast-123000542</guid>
<pubDate>Wed, 26 Feb 2025 12:30:00 GMT</pubDate>
<description>Designation applies to the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) whose disease has progressed following treatment with platinum-based chemotherapy and an anti-PD-(L)1 antibodyBOSTON, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Fas</description>
</item>
</channel>
</rss>